November 19, 2012
Flagship qPCR instrument offers reliability, accuracy, ease of use and flexibility for IVD and lab-developed diagnostic tests
Life Technologies Corporation
) today announced the launch of its Applied Biosystems QuantStudio™ Dx Real-Time PCR Instrument designed to meet the specific needs of clinical diagnostic laboratories. The instrument is CE-IVD marked for use in
and represents a significant extension of Life Technologies' product offerings in the diagnostics arena.
"Molecular diagnostic tests based on real-time PCR have become indispensable to the clinical lab," said
, president of Medical Sciences at Life Technologies. "Molecular testing is the fastest-growing segment of the diagnostics market, and the QuantStudio™ Dx instrument has unique features that will allow us to capture that market growth."
The global IVD (in vitro diagnostic) market is approximately
and is expected to reach
by 2015. The current European IVD market is approximately
and expected to reach
The QuantStudio™ Dx Real-Time PCR Instrument can perform numerous diagnostic functions, including pathogen detection, gene expression analysis, SNP genotyping, copy number analysis, mutation detection, micro-RNA and other non-coding RNA analysis, and high-resolution melt analysis.
The instrument's touchscreen, reagent and sample tracking, and LIMS (Laboratory Information Management Systems) interface are specifically designed for ease of use. Flexibility is enabled through easily interchangeable thermal cycling blocks that accommodate 96- or 384-well plates and a proprietary qPCR microfluidics card, which can perform 48 tests on eight samples simultaneously without the need for liquid-handling robots. The card can also be used to design and implement custom tests. Life Technologies is currently developing diagnostic tests utilizing this format.